The global antidiabetic drug market is expected to
witness substantial growth over the forecast period on account of increasing
occurrence of diabetes; both type I and type II and increasing obesity among
people across the globe. Type I and type II diabetes is expected to foster the
demand for oral hypoglycemic drugs as it is a proven way to control diabetes
among patients globally.
According to International Diabetes Federation,
incidences of diabetes and related disorders are anticipated to grow over the
forecast period owing to the changing lifestyles and increasing geriatric
population across the world. According to International Diabetes Foundation
(IDF), obesity and diabetes share a fundamental relationship are expected to be
the biggest challenge for public health in the forecast period. Furthermore,
unregulated dietary habits are anticipated to increase the occurrence of
diabetes among people, in turn, leading to increasing demand for antidiabetic
drugs.
Browse Detail Report@
There has been a considerable advancement in the
healthcare and pharmaceutical sectors owing to increasing demand for healthcare
services and medical facilities. The rising expenditure on healthcare
facilities has led pharmaceutical industry to innovate and come up with new
advanced drugs. Similarly, owing to the increasing number of diabetic patients,
pharmaceutical companies have been innovating and have come up with various
methods to control diabetes. However, controlling type II diabetes has posed a challenge
for the industry as it affects the processing of blood sugar in the body. New
advanced drugs are available in the market for this type of diabetes. The
demand for the antidiabetic drug is anticipated to increase mostly owing to the
changing lifestyle of people and irregular dietary habits.
There are various antidiabetic drugs and ways to treat
diabetes such as insulin, sensitizers, secretagogues, alpha-glucosidase
inhibitors, peptide analogs and glycosurics. Insulin is used to treat type I
diabetes as it reduces the capacity of the pancreas to form insulin inside the
body. The insulin is by injecting it into the body. Types of insulin on the
basis of their reaction time once injected in the body are rapid acting
insulin, intermediate insulin and long acting insulin. Sensitizers are two
types of biguanides and thiazolidinediones. Sensitizers are used to treat type
II diabetes as it is insulin resistant.
Biguanides are further bifurcated into metformin,
phenformin and buformin. Metformin is majorly used oral drugs that do lead to
weight gain. Few examples of thiazolidinediones are roziglitazone, pioglitazone
and troglitazone. Secretagogues are classified into two types, sulfonylureas
and non-sulfonylureas. Secretagogues are used to treat diabetes type I as they
increase the insulin produncing capacity of the pancreas. Alpha-glucosidase
inhibitors unlike other drugs do not help in insulin secretion but slows down
the digestion rate of starch in the small intestine to match the impaired
insulin response.
The market of North America is expected to grow over the
forecast period on account of demand for rapid and long acting insulin analogs
owing to the increasing consumer awareness levels, healthcare expenditures and
sophisticated infrastructure. In Latin America, the consumer disposable income
is low and consumers are unable to pay for the expensive drugs owing to which
market has been witnessing sluggish growth. However, governments and private
companies are anticipated to work together for supply inexpensive drugs in the
market which is expected to increase the demand for antidiabetic drugs in the
forecast period. The improved technology has led to the manufacturing drugs at
the low cost making it affordable for consumers with low per capita incomes.
The European market is expected to grow on account of
increasing consumer awareness and obesity among the population. The developing
healthcare infrastructure is another factor for market growth. The Asia Pacific
market is expected to grow substantially owing to increasing consumer
disposable income, healthcare expenditures and growing incidences of type I and
type II diabetes. The market of the Middle East & Africa is expected to
grow during the forecast period owing to the increasing population and high disposable
income in part of the Middle East such as Dubai and Qatar. Middle class is
growing is Africa leading to increased consumer spending capacity and rising
irregular dietary habits leading to increasing occurrences of diabetes and
related disorders, in turn, increasing the demand for antidiabetic drugs.
Key players of the antidiabetics drug market include
Sanofi-Aventis, Eli Lilly, Oramed Pharmaceuticals, Takeda Pharmaceuticals,
Boehringer Ingelheim, Merck & Co. Inc., Novo Nordisk, Halozyme
Therapeutics, Bristol-Myers Squibb, Pfizer, Tonghua Dongbao, Biocon and
Wockhardt.
Browse Related
Category Market Reports @
About
Us:
Hexa Research is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact
Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Follow us
on Linkedin: https://www.linkedin.com/company/hexa-research
No comments:
Post a Comment